Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity.
Animals
Blood-Brain Barrier
/ chemistry
Brain Neoplasms
/ drug therapy
Capillary Permeability
Cell Line, Tumor
Drug Delivery Systems
/ methods
Drug Evaluation, Preclinical
/ methods
Female
Glioma
/ drug therapy
Humans
Magnetic Resonance Imaging
/ methods
Mice
Mice, Inbred NOD
Mice, SCID
Nanomedicine
/ methods
Nanoparticles
/ administration & dosage
Xenograft Model Antitumor Assays
High-grade glioma
blood-brain barrier
nanoparticle-based therapies
preclinical mouse model
vascular permeability
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
03
2020
accepted:
30
04
2020
entrez:
3
6
2020
pubmed:
3
6
2020
medline:
19
5
2021
Statut:
epublish
Résumé
The clinical translation of new nanoparticle-based therapies for high-grade glioma (HGG) remains extremely poor. This has partly been due to the lack of suitable preclinical mouse models capable of replicating the complex characteristics of recurrent HGG (rHGG), namely the heterogeneous structural and functional characteristics of the blood-brain barrier (BBB). The goal of this study is to compare the characteristics of the tumor BBB of rHGG with two different mouse models of HGG, the ubiquitously used U87 cell line xenograft model and a patient-derived cell line WK1 xenograft model, in order to assess their suitability for nanomedicine research.
Identifiants
pubmed: 32483457
doi: 10.7150/thno.46468
pii: thnov10p6361
pmc: PMC7255036
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6361-6371Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
J Clin Invest. 2006 Apr;116(4):847-52
pubmed: 16585951
BMC Neurosci. 2008 Feb 26;9:29
pubmed: 18302779
J Digit Imaging. 2013 Dec;26(6):1045-57
pubmed: 23884657
Fluids Barriers CNS. 2018 Sep 20;15(1):24
pubmed: 30231925
J Magn Reson. 2010 Oct;206(2):190-9
pubmed: 20674422
Neuro Oncol. 2018 Jan 10;20(1):113-122
pubmed: 29016865
Clin Cancer Res. 2000 Jun;6(6):2562-72
pubmed: 10873113
Front Oncol. 2018 Oct 15;8:419
pubmed: 30374421
Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S134-9
pubmed: 14508091
Biomaterials. 2020 Mar;235:119783
pubmed: 31981762
Adv Drug Deliv Rev. 2018 Nov - Dec;136-137:49-61
pubmed: 30308226
Trends Biotechnol. 2018 Mar;36(3):242-251
pubmed: 29310843
Cancer Cell. 2013 Feb 11;23(2):238-48
pubmed: 23410976
Exp Ther Med. 2016 Sep;12(3):1639-1644
pubmed: 27602081
Mol Imaging Biol. 2017 Oct;19(5):673-682
pubmed: 28265853
Med Image Anal. 2001 Jun;5(2):143-56
pubmed: 11516708
Neuro Oncol. 2015 Nov;17 Suppl 6:vi1-26
pubmed: 26403167
Expert Rev Neurother. 2007 Apr;7(4):363-72
pubmed: 17425491
J Neurooncol. 2009 Jan;91(2):117-25
pubmed: 18813876
Sci Rep. 2017 Oct 24;7(1):13894
pubmed: 29066764
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
MAGMA. 2015 Dec;28(6):555-63
pubmed: 26239630
Annu Rev Pathol. 2011;6:95-119
pubmed: 20936938
Neuroimage. 2019 Nov 15;202:116137
pubmed: 31473352
Adv Drug Deliv Rev. 2012 Jan;64(1):53-68
pubmed: 21983328
Cancers (Basel). 2013 Apr 03;5(2):357-71
pubmed: 24216981
Magn Reson Med. 1991 Feb;17(2):357-67
pubmed: 2062210
Nanomedicine (Lond). 2018 Mar;13(6):579-583
pubmed: 29376468
Sci Rep. 2019 Mar 20;9(1):4902
pubmed: 30894629
Nat Commun. 2018 Nov 21;9(1):4904
pubmed: 30464169
Neuroimage. 2002 Oct;17(2):825-41
pubmed: 12377157
Front Oncol. 2014 Jul 21;4:126
pubmed: 25101239
Neuro Oncol. 2012 Aug;14(8):979-93
pubmed: 22679124
Theranostics. 2018 Feb 4;8(5):1435-1448
pubmed: 29507632
Biochem Biophys Res Commun. 2015 Dec 18;468(3):485-9
pubmed: 26116770
ACS Nano. 2018 Nov 27;12(11):11355-11365
pubmed: 30375848
Neuroimage. 2011 Feb 1;54(3):2033-44
pubmed: 20851191
Theranostics. 2018 Apr 30;8(11):3126-3137
pubmed: 29896307
J Magn Reson Imaging. 2014 May;39(5):1314-9
pubmed: 24123598
Theranostics. 2017 Aug 15;7(14):3489-3503
pubmed: 28912890
Acta Pharm Sin B. 2014 Jun;4(3):193-201
pubmed: 26579383
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
Neuro Oncol. 2018 Jan 22;20(2):184-191
pubmed: 29016900
J Neurooncol. 2007 Nov;85(2):133-48
pubmed: 17874037
Theranostics. 2020 Jan 1;10(3):1355-1372
pubmed: 31938069
J Magn Reson Imaging. 1999 Sep;10(3):223-32
pubmed: 10508281
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Histol Histopathol. 2009 Jul;24(7):879-91
pubmed: 19475534